Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO

Launched by UNIVERSITY HOSPITAL, LILLE · Jan 16, 2023

Keywords

ClinConnect Summary

This clinical trial is studying two different ways to give blood transfusions to patients who are receiving a special treatment called veno-arterial extracorporeal membrane oxygenation (VA-ECMO) because of severe heart problems known as cardiogenic shock. One method focuses on each patient's individual needs based on their body’s oxygen levels, while the other method uses a standard guideline based on how much hemoglobin (a protein in blood) is present. The main goal is to see which method requires fewer blood transfusions, while also looking at factors like survival rates, overall health, and the cost of treatment.

To participate in this trial, individuals must be at least 18 years old and receiving VA-ECMO for cardiogenic shock, with a life expectancy of more than 90 days. They also need to have a special line placed in their body to measure oxygen levels in the blood. However, those who are pregnant, do not have health insurance, refuse blood transfusions, or have certain medical conditions may not be eligible. Participants can expect close monitoring and care throughout the study, and their involvement will help improve how blood transfusions are managed in critical situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age of 18 and older,
• • supported by peripheral VA-ECMO
• • for cardiogenic shock
• • Life expentency \>90 days
• • Central venous line available ScVO2 measurement
• Exclusion Criteria:
• • Pregnancy,
• • Lack of health insurance,
• • Opposition to blood transfusion,
• • Known congenital hemoglobin disease or disorder,
• • Metabolic alcaloosis with pH\>7.8,
• • eCPR,
• • Legally incapacitated adults